PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29717476-2	2019	Verified DDI simulations provided dose recommendations for olaparib coadministration with clinically relevant CYP3A4 modulators to eliminate potential risk to patient safety or olaparib efficacy.	olaparib	59-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116	
29717476-3	2019	When olaparib is given with strong/moderate CYP3A inhibitors, the dose should be reduced to 100/150 mg b.i.d.	olaparib	5-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49	
29717476-8	2019	Olaparib was shown to be a weak inhibitor of CYP3A (1.6-fold increase in exposure of a sensitive CYP3A probe) and to have no effect on P-glycoprotein or UGT1A1 substrates.	olaparib	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-50	
29717476-8	2019	Olaparib was shown to be a weak inhibitor of CYP3A (1.6-fold increase in exposure of a sensitive CYP3A probe) and to have no effect on P-glycoprotein or UGT1A1 substrates.	olaparib	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102	
30730634-11	2017	Olaparib is metabolised in the liver, mainly by cytochrome P450 isoenzymes CYP3A4 and CYP3A5.	olaparib	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81	
28657402-8	2018	In a further study, olaparib (2-200 muM) functioned as a time-dependent inhibitor of CYP3A4/5 (KI, 72.2 muM and Kinact, 0.0675 min-1).	olaparib	20-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91	
28657402-9	2018	Assessment of the CYP induction potential of olaparib (0.061-44 muM) showed minor concentration-related increases in CYP1A2 and more marked increases in CYP2B6 and CYP3A4 mRNA, compared with positive control activity; however, no significant change in CYP3A4/5 enzyme activity was observed.	olaparib	45-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170	
28657402-9	2018	Assessment of the CYP induction potential of olaparib (0.061-44 muM) showed minor concentration-related increases in CYP1A2 and more marked increases in CYP2B6 and CYP3A4 mRNA, compared with positive control activity; however, no significant change in CYP3A4/5 enzyme activity was observed.	olaparib	45-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	252-258	
27745744-1	2016	PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5).	olaparib	27-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	227-233	
27745744-2	2016	We assessed the potential of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) to alter the pharmacokinetic (PK) profile of olaparib following single oral tablet doses.	olaparib	131-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37	
27745744-13	2016	IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone.	olaparib	26-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106	
27745744-13	2016	IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone.	olaparib	26-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	196-202	
27745744-14	2016	Potent CYP3A4 enzyme inhibitors and inducers should be avoided during olaparib treatment.	olaparib	70-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13